SG2014010995A - Animal models and therapeutic molecules - Google Patents

Animal models and therapeutic molecules

Info

Publication number
SG2014010995A
SG2014010995A SG2014010995A SG2014010995A SG2014010995A SG 2014010995 A SG2014010995 A SG 2014010995A SG 2014010995 A SG2014010995 A SG 2014010995A SG 2014010995 A SG2014010995 A SG 2014010995A SG 2014010995 A SG2014010995 A SG 2014010995A
Authority
SG
Singapore
Prior art keywords
animal models
therapeutic molecules
therapeutic
molecules
models
Prior art date
Application number
SG2014010995A
Other languages
English (en)
Inventor
Bradley Allan
Lee E-Chiang
Liang Qi
Wang Wei
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43428834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG2014010995(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0911846.4A external-priority patent/GB0911846D0/en
Priority claimed from GB0913102A external-priority patent/GB0913102D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of SG2014010995A publication Critical patent/SG2014010995A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG2014010995A 2009-07-08 2010-07-07 Animal models and therapeutic molecules SG2014010995A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22396009P 2009-07-08 2009-07-08
GBGB0911846.4A GB0911846D0 (en) 2009-07-08 2009-07-08 Animal models and therapeutic molecules
GB0913102A GB0913102D0 (en) 2009-07-28 2009-07-28 Animal models and therapeutic molesules
US35566610P 2010-06-17 2010-06-17

Publications (1)

Publication Number Publication Date
SG2014010995A true SG2014010995A (en) 2014-05-29

Family

ID=43428834

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2014010995A SG2014010995A (en) 2009-07-08 2010-07-07 Animal models and therapeutic molecules
SG2011096427A SG177380A1 (en) 2009-07-08 2010-07-07 Animal models and therapeutic molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011096427A SG177380A1 (en) 2009-07-08 2010-07-07 Animal models and therapeutic molecules

Country Status (22)

Country Link
US (33) US20120204278A1 (cg-RX-API-DMAC7.html)
EP (19) EP3888457B1 (cg-RX-API-DMAC7.html)
JP (7) JP5944312B2 (cg-RX-API-DMAC7.html)
KR (1) KR101875233B1 (cg-RX-API-DMAC7.html)
CN (2) CN105340834B (cg-RX-API-DMAC7.html)
AU (4) AU2010269978B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012000536A2 (cg-RX-API-DMAC7.html)
CA (1) CA2767436A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126083T1 (cg-RX-API-DMAC7.html)
DK (12) DK2798950T4 (cg-RX-API-DMAC7.html)
ES (10) ES2403087T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20130253T1 (cg-RX-API-DMAC7.html)
HU (2) HUE061788T2 (cg-RX-API-DMAC7.html)
LT (1) LT3241435T (cg-RX-API-DMAC7.html)
NO (1) NO2792236T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ597481A (cg-RX-API-DMAC7.html)
PL (4) PL2564695T3 (cg-RX-API-DMAC7.html)
PT (4) PT2421357E (cg-RX-API-DMAC7.html)
SG (2) SG2014010995A (cg-RX-API-DMAC7.html)
SI (2) SI2421357T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201300046B (cg-RX-API-DMAC7.html)
WO (1) WO2011004192A1 (cg-RX-API-DMAC7.html)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NO2792236T3 (cg-RX-API-DMAC7.html) 2009-07-08 2018-04-14
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
CN105695415A (zh) * 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
ME02902B (me) * 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RS55495B1 (sr) * 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
ES2946169T3 (es) * 2011-02-25 2023-07-13 Regeneron Pharma Ratones ADAM6
CN108220297A (zh) 2011-03-09 2018-06-29 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
IL273982B2 (en) * 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) * 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
GB2495083A (en) * 2011-09-26 2013-04-03 Kymab Ltd Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US10092638B2 (en) 2011-10-03 2018-10-09 Duke University GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
KR20250021626A (ko) * 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
CN104039133B (zh) 2011-10-28 2018-05-04 瑞泽恩制药公司 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
ES2858978T3 (es) * 2011-10-28 2021-09-30 Regeneron Pharma Ratones con receptores de linfocitos T genéticamente modificados
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
BR112014015238B1 (pt) * 2011-12-20 2022-11-16 Regeneron Pharmaceuticals, Inc Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
HRP20192218T1 (hr) * 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
CA2865029A1 (en) * 2012-03-06 2013-09-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CN106318951A (zh) 2012-03-16 2017-01-11 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2831245A1 (en) 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
MX364449B (es) * 2012-06-12 2019-04-26 Regeneron Pharma Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
NZ703973A (en) 2012-08-03 2018-04-27 Sab Llc Complex chromosome engineering for production of human antibodies in transgenic animals
EP3653049B1 (en) * 2012-12-14 2023-09-13 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
SG11201505713YA (en) 2013-02-06 2015-08-28 Regeneron Pharma B cell lineage based immunogen design with humanized animals
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2844174T3 (es) * 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
RU2704283C9 (ru) * 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
FI3169778T3 (fi) 2014-07-14 2023-12-13 Univ Washington State Ituradan soluja ablatoiva nanos-geeninpoisto
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
US10362771B2 (en) * 2014-11-20 2019-07-30 Kyoto University Method for knock-in of DNA into target region of mammalian genome, and cell
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN107666828B (zh) 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2017163049A1 (en) 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
NZ747857A (en) 2016-05-20 2023-01-27 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN117736325A (zh) 2016-08-09 2024-03-22 科马布有限公司 分离抗体及其应用
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
DK4082334T3 (da) * 2016-11-04 2025-06-02 Regeneron Pharma Ikke humane dyr med et modificeret immunglobulin-lambda-letkædelocus
PT3558369T (pt) 2016-12-21 2025-05-06 Cephalon Llc Anticorpos que se ligam especificamente à il-15 humana e suas utilizações
KR102777514B1 (ko) 2017-01-19 2025-03-06 옴니에이비 오퍼레이션스, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
EP3583118B1 (en) 2017-02-17 2025-06-11 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
KR20200038490A (ko) * 2017-08-01 2020-04-13 시티 오브 호프 항-il1rap 항체
BR112020007823A2 (pt) 2017-10-20 2020-10-27 Fred Hutchinson Cancer Research Center sistemas e métodos para produzir células b geneticamente modificadas para expressar anticorpos selecionados
WO2019113065A1 (en) 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
CN108486126A (zh) * 2018-03-27 2018-09-04 重庆金迈博生物科技有限公司 一种核酸分子及其在人源化抗体中的应用
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
EP4596043A3 (en) 2018-04-06 2025-10-01 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
GB2576914A (en) * 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
JP7560476B2 (ja) 2019-04-09 2024-10-02 アブクロ，インク． キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体
US20220330532A1 (en) * 2019-06-05 2022-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
MX2022006495A (es) 2019-11-29 2022-09-07 Kymab Ltd Tratamiento para la sobrecarga fisiologica de hierro.
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus
JP2023541216A (ja) 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
KR20230084157A (ko) 2020-10-08 2023-06-12 주식회사 휴맵 인간화 면역글로불린 유전자좌를 포함하는 게놈을 가지는 형질전환 비인간-동물 제조방법
JP2024500251A (ja) * 2020-12-09 2024-01-05 トリアンニ，インコーポレーテッド 重鎖のみ抗体
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
US12371475B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
AU2022320627A1 (en) 2021-07-26 2024-02-08 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023097236A1 (en) * 2021-11-24 2023-06-01 The Rockefeller University Compositions and methods for generating immunoglobulin knock-in mice
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
CN120035380A (zh) * 2023-09-15 2025-05-23 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
CN120813244A (zh) * 2024-02-07 2025-10-17 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US114985A (en) * 1871-05-16 Improvement in apparatus for cooling and preserving milk and other liquids
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4720449A (en) 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5859307A (en) 1992-02-04 1999-01-12 Massachusetts Institute Of Technology Mutant RAG-1 deficient animals having no mature B and T lymphocytes
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE4331162A1 (de) 1993-09-14 1995-03-16 Bayer Ag Verfahren zur Herstellung von Cyaninfarbstoffen
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0907726A4 (en) 1996-06-26 2001-11-07 Baylor College Medicine CHROMOSOMAL REORDERING BY INSERTING TWO RECOMBINATION SUBSTRATES
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20020088019A1 (en) 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
AU760113C (en) 1997-11-18 2004-04-22 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
US6509156B1 (en) 1997-12-05 2003-01-21 Europaisches Laboratorium Fur Molekularoiologie (Embl) DNA cloning method relying on the E. coli recE/recT recombination system
EP0939120A1 (en) 1998-02-27 1999-09-01 Gesellschaft für biotechnologische Forschung mbH (GBF) Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2373221A1 (en) 1999-05-03 2000-11-30 Yashwant M. Deo Human antibodies to staphylococcus aureus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2307503A1 (en) * 2000-05-02 2001-11-02 Carlos F. Barbas Iii Peptides for use as a vaccine or treatment for hiv infection
IL154063A0 (en) * 2000-07-21 2003-07-31 Us Agriculture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002040685A2 (en) * 2000-11-16 2002-05-23 Cornell Research Foundation, Inc. Vectors for conditional gene inactivation
CN1486365B (zh) 2000-11-17 2010-05-12 协和发酵麒麟株式会社 异种(人类)免疫球蛋白在克隆转基因有蹄类动物中的表达
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
ES2389251T3 (es) * 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
JP2003000243A (ja) 2001-06-25 2003-01-07 Takachika Azuma 変異体の製造法
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
AU2002331077A1 (en) 2001-08-13 2003-03-03 Amberwave Systems Corporation Dram trench capacitor and method of making the same
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
AU2003214842A1 (en) 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
JP2005537805A (ja) 2002-09-09 2005-12-15 カリフォルニア インスティチュート オブ テクノロジー ヒト化マウスを作成するための方法および組成物
WO2004030623A2 (en) 2002-10-01 2004-04-15 Mitos Pharmaceuticals, Inc. Nitroxide radioprotector formulations and methods of use
DE10251918A1 (de) * 2002-11-08 2004-05-19 Horn, Carsten, Dipl.-Biochem. Dr. Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen
US7700356B2 (en) 2002-11-08 2010-04-20 The United States Of America As Represented By The Secretary Of Agriculture System for gene targeting and producing stable genomic transgene insertions
CL2003002461A1 (es) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
GB2398784B (en) * 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
CN103205436B (zh) 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
US7604994B2 (en) 2003-09-03 2009-10-20 Morphotek, Inc. Genetically altered antibody-producing cell lines with improved antibody characteristics
CA2445602C (en) 2003-10-20 2014-01-14 Campusgen Gmbh Nucleotide sequence for creatinine deiminase and method of use
KR101333449B1 (ko) 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ｉｐ―１０ 항체 및 그의 용도
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
EP1729804A2 (en) 2004-03-19 2006-12-13 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
ES2523661T3 (es) 2004-07-22 2014-11-28 Erasmus University Medical Center Rotterdam Moléculas de unión
FR2875239B1 (fr) 2004-09-10 2007-07-20 Inst Necker Ass Loi De 1901 Procede pour l'acceleration des mutations somatiques et son application en proteomique
CN101076542A (zh) 2004-09-13 2007-11-21 伊沃詹尼克斯有限公司 特异性针对肝细胞癌和其他癌的抗体及其用途
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
WO2006047367A2 (en) 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
WO2006055704A2 (en) 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
EP1896578A4 (en) 2005-05-14 2008-11-05 Univ Fudan PIGGYBAC AS A TOOL FOR GENETIC HANDLING AND ANALYSIS IN VERTEBRATES
EP1780272A1 (en) 2005-10-27 2007-05-02 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for enhancing somatic hypermutation, gene conversion and class switch recombination
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
RU2435784C2 (ru) * 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Получение антител из одних тяжелых цепей в трансгенных животных
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007345747A1 (en) * 2006-06-27 2008-08-07 Vaxdesign Corporation Models for vaccine assessment
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
US7778624B2 (en) * 2006-09-01 2010-08-17 Wanda Ying Li Outdoor umbrella with audio system
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
PL2125889T3 (pl) 2007-02-21 2014-06-30 Univ Massachusetts Ludzkie przeciwciała przeciwko wirusowi żółtaczki typu C (HCV) i ich zastosowania
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
WO2009013620A2 (en) * 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
US7988967B2 (en) 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
CA2701646C (en) * 2007-10-12 2019-02-26 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
CA2708776A1 (en) 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2009094178A2 (en) 2008-01-25 2009-07-30 Cabot Corporation Method of preparing modified colored pigments
KR101409375B1 (ko) 2008-01-31 2014-06-18 삼성전자주식회사 반도체 메모리장치의 블록 디코딩 회로
CA2718517A1 (en) 2008-03-26 2009-10-01 Iti Scotland Limited Efficient insertion of dna into embryonic stem cells
EP2271758B1 (en) 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
CN102123582B (zh) 2008-06-27 2015-09-30 莫鲁斯有限公司 产生抗体的非人哺乳动物
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20110314563A1 (en) 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
CA2983133A1 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
ES2498765T3 (es) 2009-04-03 2014-09-25 Medical Research Council Mutantes de la citidina desaminasa inducida por activación (AID) y procedimientos de uso
KR101829073B1 (ko) 2009-06-26 2018-02-13 아이2 파마슈티컬스, 인크. 대리 경쇄의 발현
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NO2792236T3 (cg-RX-API-DMAC7.html) 2009-07-08 2018-04-14
GB0911846D0 (en) 2009-07-08 2009-08-19 Genome Res Ltd Animal models and therapeutic molecules
GB0913102D0 (en) 2009-07-28 2009-09-02 Genome Res Ltd Animal models and therapeutic molesules
ES2666584T3 (es) 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP5756802B2 (ja) 2009-08-13 2015-07-29 クリスタル バイオサイエンス インク．Ｃｒｙｓｔａｌ Ｂｉｏｓｃｉｅｎｃｅ Ｉｎｃ． 最小ｃｄｒを有する抗体を産生するトランスジェニック動物
JP2013509878A (ja) 2009-11-05 2013-03-21 アナプティスバイオ インコーポレイティッド 鎖シャフリングおよび任意に体細胞超変異を用いる、改善された抗原結合物質の生成方法
US20120233715A1 (en) 2009-11-17 2012-09-13 Kyowa Hakko Kirin Co., Ltd Human artificial chromosome vector
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
EP2571512B1 (en) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
CN105695415A (zh) 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
ME02902B (me) 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
US20120195910A1 (en) 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
ES2946169T3 (es) 2011-02-25 2023-07-13 Regeneron Pharma Ratones ADAM6
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20250021626A (ko) 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US20180295821A1 (en) 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
BR112014015238B1 (pt) 2011-12-20 2022-11-16 Regeneron Pharmaceuticals, Inc Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
HRP20192218T1 (hr) 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
BR112014021251A2 (pt) 2012-03-02 2017-06-27 Regeneron Pharma anticorpos humanos para toxinas de clostridium difficile
CA2865029A1 (en) 2012-03-06 2013-09-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CN106318951A (zh) 2012-03-16 2017-01-11 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2831245A1 (en) 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
GB2537000C (en) 2012-05-25 2019-10-09 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8518765B1 (en) 2012-06-05 2013-08-27 Intermolecular, Inc. Aqua regia and hydrogen peroxide HCl combination to remove Ni and NiPt residues
MX364449B (es) 2012-06-12 2019-04-26 Regeneron Pharma Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
EP2918681B1 (en) 2012-11-09 2022-03-23 Shenzhen Institute Of Molecular Crop Design Fertility gene and uses thereof
IL239317B (en) 2012-12-12 2022-07-01 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US20150033372A1 (en) 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783618B2 (en) * 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US20140331339A1 (en) 2013-05-03 2014-11-06 Kymab Limited Transgenic Non-Human Assay Vertebrates, Assays and Kits
US20140331344A1 (en) 2013-05-03 2014-11-06 Kymab Ltd. Transgenic Animals
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
JP7087648B2 (ja) * 2018-05-08 2022-06-21 トヨタ自動車株式会社 電池パック

Also Published As

Publication number Publication date
AU2018206729B2 (en) 2020-10-08
DK2604110T3 (en) 2017-02-13
DK2792236T4 (da) 2023-05-15
ES2403087T3 (es) 2013-05-14
DK2517556T4 (da) 2023-05-15
US20170101482A1 (en) 2017-04-13
CA2767436A1 (en) 2011-01-13
EP3871497A1 (en) 2021-09-01
DK2517557T3 (en) 2016-05-30
US20150040250A1 (en) 2015-02-05
EP3622813B1 (en) 2021-02-17
EP2421357B1 (en) 2013-01-23
US11606941B2 (en) 2023-03-21
EP4014729A1 (en) 2022-06-22
US20140201856A1 (en) 2014-07-17
DK2798950T4 (da) 2023-05-15
DK3241435T3 (da) 2021-08-23
EP3241435B1 (en) 2021-05-26
PT2564695E (pt) 2015-06-03
JP7141427B2 (ja) 2022-09-22
US20140120582A1 (en) 2014-05-01
DK3028565T3 (da) 2017-11-13
EP2517556B1 (en) 2015-11-18
JP6930695B2 (ja) 2021-09-01
DK3028564T3 (da) 2017-11-13
HK1162119A1 (en) 2012-08-24
DK3622815T3 (da) 2023-06-26
EP2604111A2 (en) 2013-06-19
SG177380A1 (en) 2012-02-28
EP3622813B2 (en) 2024-06-19
EP2604110A2 (en) 2013-06-19
US20120204278A1 (en) 2012-08-09
DK2792236T3 (en) 2018-01-02
EP2792236B1 (en) 2017-11-15
DK3622813T4 (da) 2024-09-16
US20150113669A1 (en) 2015-04-23
EP2604111A3 (en) 2013-12-18
EP3028564B2 (en) 2024-01-24
US20150334998A1 (en) 2015-11-26
US20170094956A1 (en) 2017-04-06
US20230270088A1 (en) 2023-08-31
US20160345552A1 (en) 2016-12-01
EP2792236A2 (en) 2014-10-22
US11564380B2 (en) 2023-01-31
PL2517556T3 (pl) 2016-03-31
DK2798950T3 (en) 2017-05-22
ES2948572T3 (es) 2023-09-14
EP2798950B2 (en) 2023-03-22
US20140150126A1 (en) 2014-05-29
PT2517556E (pt) 2016-01-20
JP2015126736A (ja) 2015-07-09
US9505827B2 (en) 2016-11-29
ES2537239T3 (es) 2015-06-03
US20140150125A1 (en) 2014-05-29
EP2604110A3 (en) 2013-08-14
US20130318643A1 (en) 2013-11-28
JP6612275B2 (ja) 2019-11-27
US20170099817A1 (en) 2017-04-13
US20170071174A1 (en) 2017-03-16
AU2021200079A1 (en) 2021-03-18
US11812731B2 (en) 2023-11-14
EP3622814B1 (en) 2023-11-08
US20140182003A1 (en) 2014-06-26
PL2421357T3 (pl) 2013-07-31
SI2421357T1 (sl) 2013-06-28
EP4215043A1 (en) 2023-07-26
LT3241435T (lt) 2021-10-25
NZ597481A (en) 2013-10-25
US20160044900A1 (en) 2016-02-18
US20200337280A1 (en) 2020-10-29
HUE061788T2 (hu) 2023-08-28
US20140201854A1 (en) 2014-07-17
HRP20130253T1 (hr) 2013-05-31
CN102638971B (zh) 2015-10-07
HK1201026A1 (en) 2015-08-21
EP2517557A3 (en) 2013-07-24
ES2974417T3 (es) 2024-06-27
EP2798950B1 (en) 2017-04-19
WO2011004192A1 (en) 2011-01-13
EP3028564A1 (en) 2016-06-08
SI3241435T1 (sl) 2021-11-30
HK1180535A1 (en) 2013-10-25
HUE055817T2 (hu) 2021-12-28
PT3241435T (pt) 2021-08-26
US10165763B2 (en) 2019-01-01
AU2016244326A1 (en) 2016-11-03
JP5944312B2 (ja) 2016-07-05
EP2792236B2 (en) 2023-03-22
EP3888457C0 (en) 2024-05-15
US20160345551A1 (en) 2016-12-01
ES2993214T3 (en) 2024-12-26
EP3871497C0 (en) 2024-02-28
HK1172207A1 (en) 2013-04-19
JP6876853B2 (ja) 2021-05-26
EP2517556B2 (en) 2023-03-22
AU2021200079B2 (en) 2023-11-09
AU2010269978B2 (en) 2016-11-03
US20200352144A1 (en) 2020-11-12
US20170051045A1 (en) 2017-02-23
ES2978496T3 (es) 2024-09-13
EP4014729C0 (en) 2024-08-07
ES2884309T3 (es) 2021-12-10
ES2965212T3 (es) 2024-04-11
PL3241435T3 (pl) 2021-12-13
EP3622815B1 (en) 2023-04-05
EP3622814C0 (en) 2023-11-08
EP2798950A1 (en) 2014-11-05
US10064398B2 (en) 2018-09-04
EP3871497B1 (en) 2024-02-28
US20200375158A1 (en) 2020-12-03
EP2564695A1 (en) 2013-03-06
JP2020028296A (ja) 2020-02-27
DK3028564T5 (da) 2024-04-29
JP2020156503A (ja) 2020-10-01
CN102638971A (zh) 2012-08-15
AU2016244326B2 (en) 2018-04-26
US20140134156A1 (en) 2014-05-15
US20230225302A1 (en) 2023-07-20
AU2018206729C1 (en) 2023-08-10
DK2517556T3 (en) 2016-01-11
EP3028565A1 (en) 2016-06-08
EP3871498A1 (en) 2021-09-01
AU2018206729A1 (en) 2018-08-02
EP2517556A2 (en) 2012-10-31
EP3241435A1 (en) 2017-11-08
EP3622814A1 (en) 2020-03-18
PL2564695T3 (pl) 2015-10-30
US20200352145A1 (en) 2020-11-12
EP3622813A1 (en) 2020-03-18
US9447177B2 (en) 2016-09-20
US20130042331A2 (en) 2013-02-14
JP2017086084A (ja) 2017-05-25
EP4014729B1 (en) 2024-08-07
HK1202373A1 (en) 2015-10-02
PT2421357E (pt) 2013-04-18
SMT201300046B (it) 2013-07-09
EP2517557A2 (en) 2012-10-31
EP3888457A1 (en) 2021-10-06
BR112012000536A2 (pt) 2020-08-11
DK3622813T3 (da) 2021-05-03
EP2604110B1 (en) 2016-11-30
EP3871498B1 (en) 2024-09-25
US20230263143A1 (en) 2023-08-24
EP3622815A1 (en) 2020-03-18
US20170099815A1 (en) 2017-04-13
AU2010269978A1 (en) 2012-02-02
US20120167237A1 (en) 2012-06-28
EP3871498C0 (en) 2024-09-25
HRP20211253T1 (hr) 2021-11-12
ES2994445T3 (en) 2025-01-23
US20170099816A1 (en) 2017-04-13
CN105340834A (zh) 2016-02-24
DK2517557T4 (da) 2023-09-25
EP2517557B2 (en) 2023-08-02
KR101875233B1 (ko) 2018-07-05
EP2792236A3 (en) 2014-11-12
EP2421357A1 (en) 2012-02-29
KR20130042461A (ko) 2013-04-26
JP6088562B2 (ja) 2017-03-01
DK2421357T3 (da) 2013-04-15
EP2517556A3 (en) 2013-07-17
EP3888457B1 (en) 2024-05-15
NO2792236T3 (cg-RX-API-DMAC7.html) 2018-04-14
JP2020150951A (ja) 2020-09-24
US9434782B2 (en) 2016-09-06
CN105340834B (zh) 2018-11-06
EP2517557B1 (en) 2016-04-13
EP3028564B1 (en) 2017-09-27
DK2564695T3 (en) 2015-05-26
DK3028564T4 (da) 2024-04-22
US20170105396A1 (en) 2017-04-20
ES2557737T3 (es) 2016-01-28
JP2012532598A (ja) 2012-12-20
JP6876854B2 (ja) 2021-05-26
US20240057572A1 (en) 2024-02-22
EP3028565B1 (en) 2017-09-27
US20160150768A1 (en) 2016-06-02
EP2564695B1 (en) 2015-04-15
JP2020156502A (ja) 2020-10-01
CY1126083T1 (el) 2023-11-15

Similar Documents

Publication Publication Date Title
SG2014010995A (en) Animal models and therapeutic molecules
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0918392D0 (en) Diagnostic and therapeutic methods
EP2438167A4 (en) THERAPEUTIC AND DIAGNOSTIC MOLECULES
GB201103609D0 (en) Improvements in animal training and devices
GB0911846D0 (en) Animal models and therapeutic molecules
GB0913102D0 (en) Animal models and therapeutic molesules
GB0802128D0 (en) Therapeutic compounds and their use
HK40014468B (zh) 囓齿动物模型及治疗分子
HK1180536A (en) Animal models and therapeutic molecules
ES1071307Y (es) Carreton para entrenamiento en practicas de acoso-derribo y rejoneo
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
GB0913045D0 (en) Animal model
GB0913300D0 (en) Therapeutic compounds and their use
GB0921105D0 (en) Inhaler for humans and animals
AU2009900539A0 (en) Bacteriophage therapy in livestock